{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:50:56Z","timestamp":1787025056482,"version":"build-2736575974"},"reference-count":23,"publisher":"American Diabetes Association","issue":"8","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":4481,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,8,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>This study tested a model hypothesizing that treatment affects objective clinical outcomes, which in turn affect perceived consequences, which in turn affect satisfaction and preference judgments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>The model was tested in a double-blind, randomized clinical trial in which 266 patients with type 1 diabetes added active or placebo pramlintide to their insulin regimens. Objective clinical outcomes included changes in glucose and weight control, insulin requirements, incidence of hypoglycemia, and study drug tolerance. At the end of the trial, patients completed the validated PRAM-TSQ questionnaire measuring treatment satisfaction and preference and perceived medication benefits and side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Statistical modeling demonstrated that active pramlintide was significantly associated with greater treatment satisfaction, preference, and perceived benefits (all except hypoglycemia prevention), as well as objective clinical outcomes (weight loss, lower postprandial glucose [PPG], lower medication tolerance, more hypoglycemia). Perceptions of treatment consequences were sensitive and specific to their cognate objective clinical outcomes (no halo effects). Clinical outcomes (especially PPG) accounted for almost half of the effect of the study medication on treatment satisfaction and preference. Treatment satisfaction and preference were strongly related to the perceived benefits\/side effects of the study medication, and these perceptions (especially glucose control) mediated most of the association of clinical outcomes with satisfaction and preference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>This model received substantial empirical support. Improvements in objective clinical outcomes accounted for a large part of the association of pramlintide treatment with higher treatment satisfaction and preference. Perceived treatment consequences mediated the effect of objective clinical benefits on satisfaction with and preference for the study medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc08-2256","type":"journal-article","created":{"date-parts":[[2009,5,26]],"date-time":"2009-05-26T22:18:40Z","timestamp":1243376320000},"page":"1411-1417","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":46,"title":["How Does Treatment Satisfaction Work?"],"prefix":"10.2337","volume":"32","author":[{"given":"Mark","family":"Peyrot","sequence":"first","affiliation":[{"name":"Department of Sociology, Loyola College, Baltimore, Maryland;"},{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Rubin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland;"},{"name":"Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2009,5,26]]},"reference":[{"key":"2022031302513323000_B1","unstructured":"Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development and labeling claims. Available at http:\/\/www.fda.gov\/cder\/guidance\/5460dft.pdf. Accessed 24 March 2008"},{"key":"2022031302513323000_B2","first-page":"164","article-title":"The DIAB. &TE.S Project: how patients perceive diabetes and diabetes therapy","volume":"75","author":"Marra","year":"2004","journal-title":"Acta Biomed"},{"key":"2022031302513323000_B3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1262-3636(07)70185-4","article-title":"Electronic pill-boxes in the evaluation of oral hypoglycemic agent compliance","volume":"31","author":"Charpentier","year":"2005","journal-title":"Diabetes Metab"},{"key":"2022031302513323000_B4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1365-2702.2007.01772.x","article-title":"An evaluation of an insulin transfer programme delivered in a group setting","volume":"16","author":"Kelley","year":"2007","journal-title":"J Clin Nurs"},{"key":"2022031302513323000_B5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1742-1241.2006.01190.x","article-title":"Evaluation of glargine group-start sessions in patients with type 2 diabetes as a strategy to deliver the service","volume":"61","author":"Tahrani","year":"2007","journal-title":"Int J Clin Pract"},{"key":"2022031302513323000_B6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2337\/diacare.28.1.53","article-title":"Validation and reliability of an instrument for assessing health-related quality of life and treatment preferences: the Insulin Delivery System Rating Questionnaire","volume":"28","author":"Peyrot","year":"2005","journal-title":"Diabetes Care"},{"key":"2022031302513323000_B7","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2337\/diacare.27.10.2495","article-title":"Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70\/30 insulin aspart suspension (aspart protamine suspension\/soluble aspart) versus alternative treatment strategies","volume":"27","author":"Rubin","year":"2004","journal-title":"Diabetes Care"},{"key":"2022031302513323000_B8","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1185\/030079907X210804","article-title":"Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy","volume":"23","author":"Rubin","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"2022031302513323000_B9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/0145721708326989","article-title":"Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use","volume":"35","author":"Rubin","year":"2009","journal-title":"Diabetes Educ"},{"key":"2022031302513323000_B10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2307\/2087176","article-title":"Ecological correlations and the behavior of individuals","volume":"15","author":"Robinson","year":"1950","journal-title":"Am Sociol Rev"},{"key":"2022031302513323000_B11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2337\/diacare.8.3.305","article-title":"Modeling psychosocial effects on glucose control","volume":"8","author":"Peyrot","year":"1985","journal-title":"Diabetes Care"},{"key":"2022031302513323000_B12","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":"A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes","volume":"29","author":"Edelman","year":"2006","journal-title":"Diabetes Care"},{"key":"2022031302513323000_B13","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlinitide therapy as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"2022031302513323000_B14","volume-title":"SYMLIN [package insert]","year":"2005"},{"key":"2022031302513323000_B15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse","year":"2002","journal-title":"Diabetes Care"},{"key":"2022031302513323000_B16","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as adjunct to insulin therapy improves long-term glycemic and weight control in type 1 diabetes mellitus: a one-year randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"key":"2022031302513323000_B17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9343(91)90605-W","article-title":"Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial","volume":"90","author":"DCCT Research Group","year":"1991","journal-title":"Am J Med"},{"key":"2022031302513323000_B18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2337\/dc06-1026","article-title":"Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes","volume":"30","author":"Marrero","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031302513323000_B19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jpepsy\/21.1.3","article-title":"Causal modeling: theory and applications","volume":"21","author":"Peyrot","year":"1996","journal-title":"J Ped Psychol"},{"key":"2022031302513323000_B20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2307\/2676370","article-title":"A biopsychosocial model of glycemic control in diabetes: stress, coping and regimen adherence","volume":"40","author":"Peyrot","year":"1999","journal-title":"J Health Soc Behav"},{"key":"2022031302513323000_B21","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"2022031302513323000_B22","volume-title":"Statistical Power Analysis for the Behavioral Sciences.","author":"Cohen","year":"1969"},{"key":"2022031302513323000_B23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/dia.2008.0031","article-title":"Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with Pramlintide as an adjunct to insulin therapy","volume":"10","author":"Peyrot","year":"2008","journal-title":"Diabetes Technol Ther"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/32\/8\/1411\/603830\/zdc00809001411.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/32\/8\/1411\/603830\/zdc00809001411.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T03:09:27Z","timestamp":1647140967000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/32\/8\/1411\/38885\/How-Does-Treatment-Satisfaction-Work-Modeling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,26]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2009,5,26]]},"published-print":{"date-parts":[[2009,8,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc08-2256","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,26]]}}}